Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Eli Lilly launches Mounjaro KwikPen in India, expanding weight-loss drug options and intensifying competition with Novo Nordisk.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk announced this morning that it is ending its partnership with Hims & Hers, which allowed the telehealth provider to sell Novo's blockbuster weight-loss drug, Wegovy.

Novo Nordisk NOVO.B -0.28% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk ends its partnership with Hims & Hers over safety concerns with Wegovy distribution, citing regulatory issues and counterfeit drug risks. Read more here.

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also struggling over drug results ...